Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

Aeterna Zentaris Announces Acquisition of Exclusive, U.S. Rights to APIFINY

Thursday, April 28, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

Aeterna Zentaris Inc. (NASDAQ: AEZS) announced that, effective as of June 1, 2016, it has acquired the exclusive right to promote APIFINY┬«, the only cancer specific, non-PSA blood test to assess the risk for the presence of prostate cancer, throughout the entire United States pursuant to a new co-marketing agreement with Armune BioScience, Inc.


Read more.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal